17-191
MAP Kinase/Erk Assay Kit, non-radioactive
MAP Kinase/Erk Assay Kit is designed to measure the phosphotransferase activity of MAP (mitogen-activated protein) Kinase in immunoprecipitates & column fractions.
Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
UNSPSC Code:
12161503
NACRES:
NA.84
eCl@ss:
32161000
manufacturer/tradename
Upstate®
technique(s)
activity assay: suitable (kinase)
NCBI accession no.
UniProt accession no.
shipped in
wet ice
Quality Level
Application
MAP Kinase/Erk Assay Kit is designed to measure the phosphotransferase activity of MAP (mitogen-activated protein) Kinase in immunoprecipitates & column fractions.
Used to detect/quantify: MAP Kinase/Erk
Analysis Note
The assay kit is designed to measure the phosphotransferase activity of MAP (mitogen-activated protein) Kinase in immunoprecipitates and column fractions. The assay kit is based on phosphorylation of a specific substrate (myelin basic protein, MBP). The phosphorylated substrate is then analyzed by immunoblot analysis, probing with a monoclonal Phospho-specific MBP antibody.
Other Notes
Assay Dilution Buffer I (ADBI) (Cat.# 20-108)
MAP Kinase/Erk Substrate Cocktail II (Cat.# 20-166)
Inhibitor Cocktail (Cat.# 20-116)
Magnesium/ATP Cocktail (Cat.# 20-113)
Anti-phospho-MBP, clone P12 (Cat.# 05-429)
MAP Kinase/Erk Substrate Cocktail II (Cat.# 20-166)
Inhibitor Cocktail (Cat.# 20-116)
Magnesium/ATP Cocktail (Cat.# 20-113)
Anti-phospho-MBP, clone P12 (Cat.# 05-429)
This product is derived from bovine source. Export of this product to certain countries may be restricted. Please contact Customer Service or your local distributor to inquire about product availability and export options.
Legal Information
UPSTATE is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Storage Class
12 - Non Combustible Liquids
flash_point_f
Not applicable
flash_point_c
Not applicable
Regulatory Information
新产品
This item has
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
U Turpeinen et al.
Scandinavian journal of clinical and laboratory investigation, 54(6), 475-483 (1994-10-01)
We have developed a 'sandwich'-type time-resolved immunofluorometric assay (IFMA) for tumour necrosis factor alpha (TNF-alpha) using two monoclonal antibodies (mAb) and the streptavidin/biotin (SAB) system. In this simple and fast streptavidin/biotin IFMA (SAB-IFMA) we used streptavidin coated wells to which
A Karcher et al.
Electrophoresis, 18(7), 1173-1179 (1997-06-01)
Some representative standard pyrethroid insecticides, namely permethrin, phenotrin, cypermethrin, sanmarton and fenpropathrin, were subjected to base hydrolysis with the aim of facilitating the indirect determination of these neutral species of low water solubilities by aqueous capillary electrophoresis. This first involved
B M van den Berg
Electrophoresis, 11(10), 824-829 (1990-10-01)
To test seed lots of tomato F1 hybrid varieties for the presence of undesirable inbred seeds by electrophoresis, a method has been developed on the basis of ultrathin-layer isoelectric focusing. The method is based on the genetic variation of the
A Fisch et al.
European journal of immunology, 22(6), 1413-1419 (1992-06-01)
A series of 14 monoclonal antibodies (mAb) directed against the C-terminal part of the rat invariant gamma chain (amino acid 142-216) was generated using distinct fusion proteins that contain this gamma segment for immunization and hybridoma screening. Additional fusion protein
Ignazia Tusa et al.
Oncogene, 37(19), 2601-2614 (2018-02-28)
Malignant melanoma is among the most aggressive cancers and its incidence is increasing worldwide. Targeted therapies and immunotherapy have improved the survival of patients with metastatic melanoma in the last few years; however, available treatments are still unsatisfactory. While the
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service